特发性肺纤维化药物治疗进展
Progress in Drug Therapy for Idiopathic Pulmonary Fibrosis
DOI: 10.12677/acm.2024.1441004, PDF,   
作者: 洪 阳, 江德鹏*：重庆医科大学附属第二医院呼吸与危重医学科，重庆
关键词: 特发性肺纤维化；药物治疗；研究进展；Idiopathic Pulmonary Fibrosis； Drug Therapy； Research Progress
摘要: 特发性肺纤维化(IPF)是一种原因不明的慢性、进行性、纤维化性间质性肺疾病，其特征是肺实质不断形成疤痕，导致生活质量下降和早期死亡，通常具有特征性影像学和组织学表现。特发性肺纤维化严重影响人体的呼吸功能，临床表现为进行性呼吸困难。IPF预后差，死亡率高，目前尚无根治药物出现。尽管如此，近年来对特发性肺纤维化的研究也有所增加。这篇综述系统地阐述了特发性纤维化的药物治疗进展，希望为后续的治疗方案提供一些参考。
Abstract: Idiopathic pulmonary fibrosis (IPF) is an unexplained, chronic, progressive, fibrotic interstitial lung disease characterized by progressive scarring of the lung parenchyma, leading to a reduced quality of life and early death, often with characteristic imaging and histological findings. Idiopathic pulmonary fibrosis severely affects human respiratory function, with clinical manifestations of progressive dyspnea. IPF has a poor prognosis and high mortality rate, and no curative drug has emerged yet. Nevertheless, research on idiopathic pulmonary fibrosis has increased in recent years. This review systematically describes the therapeutic progress of idiopathic fibrosis, hoping to provide some references for subsequent treatment options.
文章引用：洪阳, 江德鹏. 特发性肺纤维化药物治疗进展[J]. 临床医学进展, 2024, 14(4): 186-191. https://doi.org/10.12677/acm.2024.1441004

参考文献

[1] Yu, D., Xiang, Y., Gou, T., et al. (2023) New Therapeutic Approaches against Pulmonary Fibrosis. Bioorganic Chemistry, 138, Article ID: 106592. [Google Scholar] [CrossRef] [PubMed]
[2] 特发性肺纤维化诊断和治疗中国专家共识[J]. 中华结核和呼吸杂志, 2016, 39(6): 427-432.
[3] Kim, H.J., Perlman, D. and Tomic, R. (2015) Natural History of Idiopathic Pulmonary Fibrosis. Respiratory Medicine, 109, 661-670. [Google Scholar] [CrossRef] [PubMed]
[4] Richeldi, L., Collard, H.R. and Jones, M.G. (2017) Idiopathic Pulmonary Fibrosis. The Lancet, 389, 1941-1952. [Google Scholar] [CrossRef] 
[5] Spagnolo, P., Kropski, J.A., Jones, M.G., et al. (2021) Idiopathic Pulmonary Fibrosis: Disease Mechanisms and Drug Development. Pharmacology & Therapeutics, 222, Article ID: 107798. [Google Scholar] [CrossRef] [PubMed]
[6] Koudstaal, T., Funke-Chambour, M., Kreuter, M., et al. (2023) Pulmonary Fibrosis: From Pathogenesis to Clinical Decision-Making. Trends in Molecular Medicine, 29, 1076-1087. [Google Scholar] [CrossRef] [PubMed]
[7] Karampitsakos, T., Juan-Guardela, B.M., Tzouvelekis, A., et al. (2023) Precision Medicine Advances in Idiopathic Pulmonary Fibrosis. EBioMedicine, 95, Article ID: 104766. [Google Scholar] [CrossRef] [PubMed]
[8] Newton, C.A., Oldham, J.M., Applegate, C., et al. (2022) The Role of Genetic Testing in Pulmonary Fibrosis: A Perspective from the Pulmonary Fibrosis Foundation Genetic Testing Work Group. Chest, 162, 394-405. [Google Scholar] [CrossRef] [PubMed]
[9] Lederer, D.J. and Martinez, F.J. (2018) Idiopathic Pulmonary Fibrosis. The New England Journal of Medicine, 378, 1811-1823. [Google Scholar] [CrossRef] 
[10] Kolb, M., Bonella, F. and Wollin, L. (2017) Therapeutic Targets in Idiopathic Pulmonary Fibrosis. Respiratory Medicine, 131, 49-57. [Google Scholar] [CrossRef] [PubMed]
[11] King, T.J., Bradford, W.Z., Castro-Bernardini, S., et al. (2014) A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. The New England Journal of Medicine, 370, 2083-2092. [Google Scholar] [CrossRef] 
[12] Richeldi, L., Du Bois, R.M., Raghu, G., et al. (2014) Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. The New England Journal of Medicine, 370, 2071-2082. [Google Scholar] [CrossRef] 
[13] Tzilas, V., Tzouvelekis, A., Ryu, J.H., et al. (2022) 2022 Update on Clinical Practice Guidelines for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis. Lancet Respiratory Medicine, 10, 729-731. [Google Scholar] [CrossRef] 
[14] Kreuter, M., Wuyts, W., Renzoni, E., et al. (2016) Antacid Therapy and Disease Outcomes in Idiopathic Pulmonary Fibrosis: A Pooled Analysis. Lancet Respiratory Medicine, 4, 381-389. [Google Scholar] [CrossRef] 
[15] Raghu, G., Anstrom, K.J., King, T.E., et al. (2012) Prednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis. The New England Journal of Medicine, 366, 1968-1977. [Google Scholar] [CrossRef] 
[16] Richeldi, L., Costabel, U., Albera, C., et al. (2020) Pamrevlumab, an Anti-Connective Tissue Growth Factor Therapy, for Idiopathic Pulmonary Fibrosis (PRAISE): A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet Respiratory Medicine, 8, 25-33. [Google Scholar] [CrossRef] 
[17] Mackinnon, A.C., Gibbons, M.A., Farnworth, S.L., et al. (2012) Regulation of Transforming Growth Factor-β1-Driven Lung Fibrosis by Galectin-3. American Journal of Respiratory and Critical Care Medicine, 185, 537-546. [Google Scholar] [CrossRef] 
[18] Raghu, G., Van Den Blink, B., Hamblin, M.J., et al. (2018) Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial. JAMA, 319, 2299-2307. [Google Scholar] [CrossRef] [PubMed]
[19] Hemmings, D.G. and Brindley, D.N. (2020) Signalling by Lysophosphatidate and Its Health Implications. Essays in Biochemistry, 64, 547-563. [Google Scholar] [CrossRef] 
[20] Cheng, P., Kaltenbach, R.F., Zhang, H., et al. (2021) Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA(1)) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases. Journal of Medicinal Chemistry, 64, 15549-15581. [Google Scholar] [CrossRef] [PubMed]
[21] Oikonomou, N., Mouratis, M.A., Tzouvelekis, A., et al. (2012) Pulmonary Autotaxin Expression Contributes to the Pathogenesis of Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 47, 566-574. [Google Scholar] [CrossRef] 
[22] Li, D., Zhao, A., Zhu, J., et al. (2023) Inhaled Lipid Nanoparticles Alleviate Established Pulmonary Fibrosis. Small, 19, E2300545. [Google Scholar] [CrossRef] [PubMed]

为你推荐